Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 160-164

  Mansfield, Michael W ^a   Heywood, Daniella M ^a   Grant, Peter J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

coagulation; fibrinolysis; non insulin dependent diabetes mellitus; women

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; CHOLESTEROL BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE;

EID: 0030027840     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.160     Document Type: Article

References (36)

1. Kannal WB, McGee DL. Diabetes and cardiovascular disease, the Framingham Study. JAMA. 1979;241:2035-2038.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131-141.
4. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North W, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
5. Yarnell J, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count arc major risk factors for ischaemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-844.
6. Kannal WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
7. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM Study in healthy men. Arterioscler Thromb. 1994;14:54-59.
8. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk for recurrent myocardial infarction. Lancet. 1987;2:3-9.
9. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo J. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
10. Marbet GA, Duckert F. Fibrinogen. In: Jespersen J, Bertina RM, Haverkate F, eds. ECAT Assay Procedures. A Manual of Laboratory Results. Dordrecht, Netherlands: Kluwer; 1992:47-55.
11. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb. 1991;11:540-546.
12. Ostermann H, Van de Loo J. Factors of the haemostatic system in diabetic patients. Haemostasis. 1986;16:386-390.
13. Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North W, Stirling Y. Haemostatic variables associated with diabetes and its complications. BMJ. 1979;2:964-966.
14. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70:380-385.
15. Gough S, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med. 1991;8:898-905.
16. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
18. Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
19. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
20. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
21. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
22. Heywood DM, Mansfield MW, Grant PJ. Factor VII:C Msp I genotype, factor VII:C levels, and features of insulin resistance in non-insulin-dependent diabetes mellitus: a link with vascular risk. Diabet Med. 1995;12(suppl 1):S35. Abstract.
23. Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand factor and fibrinolytic variables arc differently affected in the insulin resistance syndrome. J Intern Med. 1994;235:419-423.
24. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
25. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37-42.
26. Julian-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost. 1989;61:370-373.
27. Eliasson M, Evrin PE, Lundblad D, Asplund K, Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis. 1993;7:316-323.
28. Rånby M, Sundell IB, Johnson O, Ledin M-C, Dahlen G. Activity of plasminogen activator inhibitor-1 (PAI-1) in a population in Northern Sweden. Fibrinolysis. 1990;4(suppl 2):54-55.
29. Glueck CJ, Glueck HI, Stroop D, Spiers J, Hamer T, Tracy T. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med. 1993;122:412-420.
30. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
31. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
32. Siegert G, Bergmann S, Jaross W. Relationship of plasminogen activator inhibitor activity and tissue-type plasminogen activator concentration with age, sex, risk factors for coronary heart disease and life style. Fibrinolysis. 1994;8:34-36.
33. Ballicsen L, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population, 1: baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 1985;54:475-479.
34. Chan P, Pan WH. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabet Med. 1995;12:504-507.
35. Ernst E. Fibrinogen: its emerging role as a cardiovascular risk factor. Angiology. 1994;45:87-93.
36. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris: relation to gender, age and acute-phase reaction: results of the ECAT angina pectoris study group. Thromb Haemost. 1995;73:561-567.